University of Colorado

Site:	University of Colorado	Go to their website
Address:	1665 N. Ursula St.
City:	Aurora
State:	CO
Zip:	80045
Country:	USA

20 trials at this site

Phase	Trial [asc]	Trial Status	Site Status	Drug	NCT#
1	A Phase I Dose Escation Study of IPI-493	Terminated	Active	IPI-493	NCT00724425
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
1	A Study of XmAb®18087 in Subjects With NET and GIST	Active, not recruiting	Closed	XmAb18087	NCT03411915
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267
1	Continuous Dosing of Regorafenib in Patients With Advanced Malignancies	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01117623
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
1	Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506) + Moxifloxacin	NCT01339104
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
1	Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors	Ongoing, but not recruiting	Closed	BIIB022	NCT00555724
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	Active	INBRX-109 + Temozolomide	NCT03715933
1	Phase 1 Study of Oral KOS-1022 in Patients with Advanced Solid Tumors	Withdrawn	Closed	KOS-1022	Univ of Colo
1	Phase 1 Study of OSI-930 in Cancer Patients	Completed	Closed	OSI-930	NCT00513851
1	Phase I Trial of Oral PX-866	Ongoing, but not recruiting	Closed	PX-866	NCT00726583
1	Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors	Unknown	Active	Sorafenib + Vorinostat	NCT00635791
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
1	Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	Terminated	Closed	PF-052112384 + PD-0325901 OR PF-052112384 + Irinotecan	NCT01347866
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Active	Rogaratinib	NCT04595747
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722